SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond

Affiliations

¹ Providence Medical Research Center, Providence Health Care, Spokane, WA 99204, USA; Institute of Translational Health Sciences, Kidney Research Institute, and Nephrology Division, University of Washington, Seattle, WA, USA. Electronic address: katherine.tuttle@providence.org.

Comment

Katherine R Tuttle. Lancet Diabetes Endocrinol. 2021 Jan.

. 2021 Jan;9(1):3-5.

doi: 10.1016/S2213-8587(20)30374-0.

¹ Providence Medical Research Center, Providence Health Care, Spokane, WA 99204, USA; Institute of Translational Health Sciences, Kidney Research Institute, and Nephrology Division, University of Washington, Seattle, WA, USA. Electronic address: katherine.tuttle@providence.org.

No abstract available

Comment on

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Wheeler DC, et al. Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. Lancet Diabetes Endocrinol. 2021. PMID: 33338413 Clinical Trial.